John Cunningham virus
E559471
John Cunningham virus is a human polyomavirus that typically remains latent but can cause the severe demyelinating brain disease progressive multifocal leukoencephalopathy in immunocompromised individuals.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
DNA virus
ⓘ
human pathogen ⓘ non-enveloped virus ⓘ opportunistic virus ⓘ polyomavirus ⓘ |
| alsoKnownAs |
JC virus
NERFINISHED
ⓘ
JCV NERFINISHED ⓘ |
| BaltimoreClassification | Group I double-stranded DNA viruses ⓘ |
| capsidSymmetry | icosahedral ⓘ |
| causes | progressive multifocal leukoencephalopathy ⓘ |
| cellReceptor | serotonin receptor 5-HT2A (for some strains) ⓘ |
| diagnosisMethod |
PCR detection of viral DNA in cerebrospinal fluid
ⓘ
brain MRI showing multifocal white matter lesions ⓘ brain biopsy with viral inclusions ⓘ |
| diseaseType | demyelinating disease of the central nervous system ⓘ |
| enveloped | no ⓘ |
| family | Polyomaviridae NERFINISHED ⓘ |
| firstDescribed | 1971 ⓘ |
| genomeSize | approximately 5.1 kilobase pairs ⓘ |
| genomeType | circular double-stranded DNA ⓘ |
| genus | Betapolyomavirus NERFINISHED ⓘ |
| host | Homo sapiens ⓘ |
| infectionPattern | typically asymptomatic ⓘ |
| latencySite |
bone marrow
ⓘ
kidney ⓘ lymphoid tissues ⓘ |
| namedAfter | John Cunningham (patient in whom the virus was first identified) NERFINISHED ⓘ |
| oncogenicPotential | possible association with some tumors (not clearly established) ⓘ |
| pathogenesisFeature | lytic infection of oligodendrocytes leading to demyelination ⓘ |
| primaryTropism |
astrocytes
ⓘ
kidney epithelial cells ⓘ oligodendrocytes ⓘ |
| reactivationCondition |
AIDS
NERFINISHED
ⓘ
hematologic malignancy ⓘ immunosuppression ⓘ organ transplantation ⓘ treatment with natalizumab ⓘ treatment with other monoclonal antibodies affecting immunity ⓘ |
| riskGroup |
HIV-positive individuals with low CD4 counts
ⓘ
patients receiving immunosuppressive therapies ⓘ |
| seroprevalenceInAdults | 50–80 percent ⓘ |
| targetCellInPML | oligodendrocytes ⓘ |
| taxonRank | species ⓘ |
| transmissionRoute |
likely respiratory
ⓘ
oral-fecal ⓘ possibly urine exposure ⓘ |
| treatment | restoration of immune function ⓘ |
| treatmentChallenge | no specific antiviral therapy with proven efficacy ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.